Citations

Clear

4206 citation(s) found for "Yu, Chen".

Decreased Expression of Sulfatase 2 in the Brains of Alzheimer’s Disease Patients: Implications for Regulation of Neuronal Cell Signaling
Roberts, Rosebud O., Kang, Yoo Na , Moser, Catherine D., Wang, Shaoqing , Moore, Michael J. , Lai, Jinping , Petersen, Ronald C. , Roberts, Lewis R. , Chen, Chen , Lai, Jin-Ping, Chen, C , Roberts, Lewis R , Hu, Chunling , Moore, Michael J. B. , Graham, Rondell P.

Mayo Clinic

Journal of Alzheimer's Disease Reports | December 20, 2017 | Volume: 1 | Issue: 1 | Pages: 115-124

10.3233/adr-170028 | PMID 30035253 Get It

Background: The human sulfatase 1 (SULF1) and sulfatase 2 (SULF2) genes modulate cell signaling and homeostasis in many tissues. Gene expression analyses have implicated SULF2 in disease pathogenesis, including Alzheimer’s disease (AD), but changes in brain SULF2 expression have not been directly established. Objective: To investigate the expression of SULF1 and SULF2 in brain tissues from AD cases and cognitively normal controls. Methods: Autopsy tissue from AD cases ( n = 20) and age-and gender-matched cognitively normal controls ( n = 20) were identified from the Mayo Clinic Alzheimer’s Disease Patient Registry neuropathology database. Tissue slides were stained for SULF1 and SULF2 protein expression in the hippocampus and frontal lobe and an expression score computed from the proportion of cells stained and the intensity of staining (range 0 [no expression] to 9 [marked expression]). Results: SULF2 expression was reduced in AD cases. Compared to cognitively normal controls, SULF2 expression in AD cases was significantly decreased in the hippocampal Cornu Ammonis (CA) (mean score of 6.5 in cases versus 8.3 in controls; p = 0.003), in the gray matter of the parahippocampal gyrus (5.6 in cases versus 7.6 in controls; p = 0.003), and in the frontal lobe gray matter (5.4 in cases versus 7.4 in controls; p = 0.002). There was no difference in SULF1 expression in the hippocampus or frontal lobe of AD cases and controls. As expected there were no differences in SULF1 or SULF2 expression in white matter in AD cases compared to cognitively normal controls. Conclusion: Decreased SULF2 in specific regions of the brain occurs in AD.
Hybrid-denovo: a de novo OTU-picking pipeline integrating single-end and paired-end 16S sequence tags
Chen, Xianfeng , Johnson, Stephen , Wang, Junwen , Kocher, Jean‐Pierre , Jeraldo, Patricio , Chia, Nicholas , Wang, Junwen , Chia, Nicholas , Chen, Jun

Mayo Clinic

GigaScience | December 15, 2017 | Volume: 7 | Issue: 3 | Pages: No page available

10.1093/gigascience/gix129 | PMID 29267858 Get It

Abstract Background Illumina paired-end sequencing has been increasingly popular for 16S rRNA gene-based microbiota profiling. It provides higher phylogenetic resolution than single-end reads due to a longer read length. However, the reverse read (R2) often has significant low base quality, and a large proportion of R2s will be discarded after quality control, resulting in a mixture of paired-end and single-end reads. A typical 16S analysis pipeline usually processes either paired-end or single-end reads but not a mixture. Thus, the quantification accuracy and statistical power will be reduced due to the loss of a large amount of reads. As a result, rare taxa may not be detectable with the paired-end approach, or low taxonomic resolution will result in a single-end approach. Results To have both the higher phylogenetic resolution provided by paired-end reads and the higher sequence coverage by single-end reads, we propose a novel OTU-picking pipeline, hybrid-denovo, that can process a hybrid of single-end and paired-end reads. Using high-quality paired-end reads as a gold standard, we show that hybrid-denovo achieved the highest correlation with the gold standard and performed better than the approaches based on paired-end or single-end reads in terms of quantifying the microbial diversity and taxonomic abundances. By applying our method to a rheumatoid arthritis (RA) data set, we demonstrated that hybrid-denovo captured more microbial diversity and identified more RA-associated taxa than a paired-end or single-end approach. Conclusions Hybrid-denovo utilizes both paired-end and single-end 16S sequencing reads and is recommended for 16S rRNA gene targeted paired-end sequencing data.
A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure
Kawakami, Rika , Lee, Candace Y.W., Bailey, Kent R. , Schirger, John A., Chen, Horng H. , Benike, Sherry L., Cannone, Valentina , Martín, Fernando L., Sangaralingham, S. Jeson , Ichiki, Tomoko , Burnett, John C. , Kawakami, Rika , Scott, Christopher G. , Sangaralingham, S. Jeson , Kawakami, Rika

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 11, 2017 | Volume: 104 | Issue: 3 | Pages: 546-552

10.1002/cpt.974 | PMID 29226471 Get It

Cenderitide is a novel designer natriuretic peptide (NP) composed of C‐type natriuretic peptide (CNP) fused to the C‐terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to coactivate the two NP receptors, particulate guanylyl cyclase (pGC)‐A and ‐B. The rationale for its design was to achieve the renal‐enhancing and antifibrotic properties of dual receptor activation, but without clinically significant hypotension. Here we report the first clinical trial on the safety, tolerability, and cyclic guanosine monophosphate (cGMP) activating properties of Cenderitide in subjects with stable heart failure (HF). Four‐hour infusion of Cenderitide was safe, well‐tolerated, and significantly increased plasma cGMP levels and urinary cGMP excretion without adverse effects with no change in blood pressure. Thus, Cenderitide has a favorable safety profile and expected pharmacological effects in stable human HF. Our results support further investigations of Cenderitide in HF as a potential future cGMP‐enhancing therapeutic strategy.
Different mutational rates and mechanisms in human cells at pregastrulation and neurogenesis
Bae, Taejeong , Tomasini, Livia , Mariani, Jessica , Zhou, Bo , Roychowdhury, Tanmoy , Franjic, Daniel , Pletikos, Mihovil , Pattni, Reenal , Chen, Bo-Juen , Venturini, Elisa , Riley‐Gillis, Bridget , Šestan, Nenad , Urban, Alexander E. , Abyzov, Alexej , Vaccarino, Flora M. , Zhou, Bo , Vaccarino, Flora M , Abyzov, Alexej , Bae, Taejeong

Mayo Clinic

Science | December 7, 2017 | Volume: 359 | Issue: 6375 | Pages: 550-555

10.1126/science.aan8690 | PMID 29217587 Get It

Brain mutations, young and old Most neurons that make up the human brain are postmitotic, living and functioning for a very long time without renewal (see the Perspective by Lee). Bae et al. examined the genomes of single neurons from the prenatal developing human brain. Both the type of mutation and the rates of accumulation changed between gastrulation and neurogenesis. These early mutations could be generating useful neuronal diversity or could predispose individuals to later dysfunction. Lodato et al. also found that neurons take on somatic mutations as they age by sequencing single neurons from subjects aged 4 months to 82 years. Somatic mutations accumulated with increasing age and accumulated faster in individuals affected by inborn errors in DNA repair. Postmitotic mutations might only affect one neuron, but the accumulated divergence of genomes across the brain could affect function. Science , this issue p. 550 , p. 555 ; see also p. 521
Rho GTPase effectors and NAD metabolism in cancer immune suppression
Chaker, Mahmoud, Minden, Audrey , Chen, Suzie , Weiss, Robert H., Chini, Eduardo N. , Mahipal, Amit , Azmi, Asfar S. , Mahipal, Amit

Mayo Clinic

Expert Opinion on Therapeutic Targets | December 6, 2017 | Volume: 22 | Issue: 1 | Pages: 9-17

10.1080/14728222.2018.1413091 | PMID 29207896 Get It

Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markers†
Xie, Dong , Marks, Randolph S., Jiang, Gening , Sun, Zhifu , Nichols, F. P., Chen, Chang , Aubry, Marie-Christine, Jatoi, Aminah , Garces, Yolanda I. , Mansfield, Aaron S. , Wigle, Dennis A. , Molina, Julian R. , Deschamps, Claude, Allen, Mark S. , Marks, Randolph, Nichols, Frances, Zhang, Mingrui, Mansfield, Aaron, Wigle, Dennis, Molina, Julian, Sun, Zhifu , Mansfield, Aaron S , Zhang, Mingrui , Yang, Ping

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | December 6, 2017 | Volume: 53 | Issue: 6 | Pages: 1214-1222

10.1093/ejcts/ezx462 | PMID 29293957 Get It

CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Chen, Yang, Harty, Gail J., Huntley, Brenda K., Heublein, Denise M., Harders, Gerald E., Meems, Laura M.G., Pan, Shuchong, Sangaralingham, S. Jeson , Ichiki, Tomoko , Burnett, John C. , Iyer, Seethalakshmi R., Meems, Laura, Chen, Yang, Iyer, Seethalakshmi , Sangaralingham, S. Jeson

Mayo Clinic

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | November 29, 2017 | Volume: 314 | Issue: 3 | Pages: R407-R414

10.1152/ajpregu.00286.2017 | PMID 29187381 Get It

The natriuretic peptides (NPs) B-type NP (BNP) and urodilatin (URO) exert renal protective properties via the particulate guanylyl cyclase A receptor (pGC-A). As a potential renal-enhancing strategy, we engineered a novel designer peptide that we call CRRL269. CRRL269 was investigated in human cell lines and in normal canines to define potential cardiorenal enhancing actions. The mechanism of its cardiorenal selective properties was also investigated. In vitro NP receptor activity was quantified with guanosine 3′,5′-cyclic monophosphate generation. In vivo effects were determined in normal canine acute infusion studies. We observed that CRRL269 demonstrated enhanced pGC-A activity in renal compared with nonrenal cell lines. CRRL269 exerted enhanced resistance to neprilysin compared with URO. Importantly, CRRL269 exhibited significant and greater increases in urinary sodium excretion and diuresis, with less blood pressure reduction, than BNP or URO in normal canines. CRRL269 retained potent renin-angiotensin-aldosterone system (RAAS) suppressing properties shared by URO and BNP. Also, CRRL269 exerted less arterial relaxation and higher cAMP cardiomyocytes generation than BNP. CRRL269 possessed superior renal and pGC-A activating properties compared with BNP or URO in vitro. CRRL269 exerted enhanced renal actions while suppressing RAAS in vivo and with less hypotension compared with URO or BNP. Together, our study suggests that CRRL269 is a promising innovative renal-enhancing drug, with favorable protective actions targeting cardiorenal disease states through the pGC-A receptor.
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Javle, Milind , Lowery, Maeve A. , Shroff, Rachna T. , Weiss, Karl Heinz , Springfeld, Christoph , Ramanathan, Ramesh K., Sadeghi, Saeed , Macarulla, Teresa , Kelley, Robin Kate , Borbath, Ivan , Choo, Su Pin , Oh, Do‐Youn , Reungwetwattana, Thanyanan , Yeh, Kun‐Huei , Ciombor, Kristen K. , Patel, Anuradha , Porter, Dale, Isaacs, Randi , Zhu, Andrew X. , Bekaii‐Saab, Tanios , Lowery, Maeve, Goyal, Lipika , El-Khoueiry, Anthony, Chen, Li‐Tzong , van Cutsem, Eric, Ciombor, Kristen, Sen, Suman, Abou-Alfa, Ghassan K, Bekaii-Saab, Tanios S , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Philip, Philip A. , Cutsem, Eric Van , Finn, Richard S. , Sen, Suman , Abou‐Alfa, Ghassan K. , Macarulla, Teresa

Mayo Clinic

Journal of Clinical Oncology | November 28, 2017 | Volume: 36 | Issue: 3 | Pages: 276-282

10.1200/jco.2017.75.5009 | PMID 29182496 Get It

Purpose No standard treatment exists for patients with cholangiocarcinoma for whom first-line gemcitabine-based therapy fails. Fibroblast growth factor receptor 2 ( FGFR2) fusions/translocations are present in 13% to 17% of intrahepatic cholangiocarcinomas. BGJ398, an orally bioavailable, selective pan-FGFR kinase inhibitor, has shown preliminary clinical activity against tumors with FGFR alterations. Methods A multicenter, open-label, phase II study ( ClinicalTrials.gov identifier: NCT02150967) evaluated BGJ398 antitumor activity in patients age ≥ 18 years with advanced or metastatic cholangiocarcinoma containing FGFR2 fusions or other FGFR alterations whose disease had progressed while receiving prior therapy. Patients received BGJ398 125 mg once daily for 21 days, then 7 days off (28-day cycles). The primary end point was investigator-assessed overall response rate. Results Sixty-one patients (35 women; median age, 57 years) with FGFR2 fusion (n = 48), mutation (n = 8), or amplification (n = 3) participated. At the prespecified data cutoff (June 30, 2016), 50 patients had discontinued treatment. All responsive tumors contained FGFR2 fusions. The overall response rate was 14.8% (18.8% FGFR2 fusions only), disease control rate was 75.4% (83.3% FGFR2 fusions only), and estimated median progression-free survival was 5.8 months (95% CI, 4.3 to 7.6 months). Adverse events included hyperphosphatemia (72.1% all grade), fatigue (36.1%), stomatitis (29.5%), and alopecia (26.2%). Grade 3 or 4 treatment-related adverse events occurred in 25 patients (41%) and included hyperphosphatemia (16.4%), stomatitis (6.6%), and palmar-plantar erythrodysesthesia (4.9%). Conclusion BGJ398 is a first-in-class FGFR kinase inhibitor with manageable toxicities that shows meaningful clinical activity against chemotherapy-refractory cholangiocarcinoma containing FGFR2 fusions. This promising antitumor activity supports continued development of BGJ398 in this highly selected patient population.
17α‐estradiol acts through hypothalamic pro‐opiomelanocortin expressing neurons to reduce feeding behavior
Steyn, Frederik J. , Ngo, Shyuan T. , Chen, Vicky Ping , Bailey‐Downs, Lora C., Xie, Teresa, Ghadami, Martin, Brimijoin, Stephen , Freeman, Willard M. , Rubinstein, Marcelo , Low, Malcolm J. , Steyn, F J , Freeman, Willard M , Stout, Michael B

Mayo Clinic

Aging Cell | November 23, 2017 | Volume: 17 | Issue: 1 | Pages: No page available

10.1111/acel.12703 | PMID 29168299 Get It

SummaryWeight loss is an effective intervention for diminishing disease burden in obese older adults. Pharmacological interventions that reduce food intake and thereby promote weight loss may offer effective strategies to reduce age‐related disease. We previously reported that 17α‐estradiol (17α‐E2) administration elicits beneficial effects on metabolism and inflammation in old male mice. These observations were associated with reduced calorie intake. Here, we demonstrate that 17α‐E2 acts through pro‐opiomelanocortin (Pomc) expression in the arcuate nucleus (ARC) to reduce food intake and body mass in mouse models of obesity. These results confirm that 17α‐E2 modulates appetite through selective interactions within hypothalamic anorexigenic pathways. Interestingly, some peripheral markers of metabolic homeostasis were also improved in animals with near complete loss of ARC Pomc transcription. This suggests that 17α‐E2 might have central and peripheral actions that can beneficially affect metabolism cooperatively or independently.
PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer
Yang, Yinhui , He, Yundong , Chen, Jiaxiang , Pan, Yunqian , Hinten, Michael, Karnes, R. Jeffrey , Westendorf, Jennifer J., Li, Benyi , Zhu, Runzhi , Xu, Wanhai , Kohli, Manish , Bai, Yang , Zhao, Yu , Ma, Linlin , Zhang, Jun , Westendorf, Jennifer J. , Huang, Haojie

Mayo Clinic

Clinical Cancer Research | November 22, 2017 | Volume: 24 | Issue: 4 | Pages: 834-846

10.1158/1078-0432.ccr-17-2006 | PMID 29167276 Get It

Abstract Purpose: Intratumoral androgen synthesis (IAS) is a key mechanism promoting androgen receptor (AR) reactivation and antiandrogen resistance in castration-resistant prostate cancer (CRPC). However, signaling pathways driving aberrant IAS remain poorly understood. Experimental Design: The effect of components of the AKT-RUNX2-osteocalcin (OCN)–GPRC6A–CREB signaling axis on expression of steroidogenesis genes CYP11A1 and CYP17A1 and testosterone level were examined in PTEN-null human prostate cancer cell lines. Pten knockout mice were used to examine the effect of Runx2 heterozygous deletion or abiraterone acetate (ABA), a prodrug of the CYP17A1 inhibitor abiraterone on Cyp11a1 and Cyp17a1 expression, testosterone level and tumor microenvironment (TME) remodeling in vivo. Results: We uncovered that activation of the AKT–RUNX2–OCN–GPRC6A–CREB signaling axis induced expression of CYP11A1 and CYP17A1 and testosterone production in PTEN-null prostate cancer cell lines in culture. Deletion of Runx2 in Pten homozygous knockout prostate tumors decreased Cyp11a1 and Cyp17a1 expression, testosterone level, and tumor growth in castrated mice. ABA treatment also inhibited testosterone synthesis and alleviated Pten loss-induced tumorigenesis in vivo. Pten deletion induced TME remodeling, but Runx2 heterozygous deletion or ABA treatment reversed the effect of Pten loss by decreasing expression of the collagenase Mmp9. Conclusions: Abnormal RUNX2 activation plays a pivotal role in PTEN loss-induced IAS and TME remodeling, suggesting that the identified signaling cascade represents a viable target for effective treatment of PTEN-null prostate cancer, including CRPC. Clin Cancer Res; 24(4); 834–46. ©2017 AACR.